Validation of the all-comers design: Results of the TARGET-AC substudy.

[1]  A. Íñiguez,et al.  Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-Year final clinical outcomes from the MASCOT post-marketing registry. , 2019, International journal of cardiology.

[2]  Fei Ye,et al.  Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation: The ULTIMATE Trial. , 2018, Journal of the American College of Cardiology.

[3]  P. Nakaji,et al.  Letter: Enrollment-To-Screening Ratio: An Undervalued Data in Randomized Clinical Trials. , 2018, Neurosurgery.

[4]  P. Serruys,et al.  Evaluating the 'all-comers' design: a comparison of participants in two 'all-comers' PCI trials with non-participants. , 2011, European heart journal.

[5]  M. Simoons,et al.  Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization. , 2006, European heart journal.

[6]  S D Simon,et al.  Is the randomized clinical trial the gold standard of research? , 2001, Journal of andrology.

[7]  J. Lewsey,et al.  Comparing outcomes of percutaneous transluminal coronary angioplasty with coronary artery bypass grafting; can routine health service data complement and enhance randomized controlled trials? , 1999, European heart journal.

[8]  B. Sibbald,et al.  Understanding controlled trials: Why are randomised controlled trials important? , 1998 .

[9]  N. Sharpe.  Clinical Trials and the Real World: Selection Bias and Generalisability of Trial Results , 2004, Cardiovascular Drugs and Therapy.

[10]  F. Eberli,et al.  revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial , 2022 .